Description of which generation of targeted drugs amivantamab belongs to and its technical characteristics

Amivantamab (Amivantamab) is a new type of bispecific antibody-targeted drug and belongs to the next generation of targeted therapy drugs. It mainly targets two receptors, epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), and has the ability to simultaneously inhibit two key tumor signaling pathways. Compared with traditional single-target targeted drugs, evantumumab effectively overcomes the problem of tumor cells becoming resistant to single-target drugs through dual targeting, representing a new breakthrough in targeted therapy technology.

Technically, evantumumab uses a bispecific antibody design that can bind to both EGFR and MET receptors. This dual-target mechanism not only inhibits the proliferation signals of tumor cells, but also promotes the elimination of tumor cells by immune cells. The drug also utilizes the antibody-dependent cell-mediated cytotoxicity (ADCC) effect to enhance the body's immune system's attack on tumors and improve the therapeutic effect. The synergistic effect of this multiple mechanisms allows evantumumab to exhibit superior anti-cancer activity in complex tumor environments.

Evantumumab is mainly used to treat patients with non-small cell lung cancer (NSCLC) with positive insertion mutations in exon 20 of EGFRexon20. For these patients, traditional targeted drugs have limited effects and urgent clinical needs. The emergence of this drug has brought new treatment options to these patients, especially when previous chemotherapy has failed or is resistant, showing good efficacy and tolerability. The clinical application of evantumumab marks the trend of targeted therapy developing towards multi-target and multi-mechanism.

Overall, evantumumab, as a new generation of bispecific antibody-targeted drugs, breaks through the limitations of traditional single-target drugs with its innovative design and multiple mechanisms of action, and opens a new chapter in targeted treatment of lung cancer. Its technical characteristics reflect the development direction of precision medicine, and it is expected to play an important role in more tumor types in the future and promote the progress of personalized treatment.

Reference materials:https://www.drugs.com